List view / Grid view
An effective quality risk management (QRM) process ensures proactive identification and control of potential issues that may arise during development and commercialisation. Where quality is defined as the degree to which a set of intrinsic properties of a drug product, its underpinning manufacturing process, and any supporting processes fulfils the…
3 July 2014 | By GlaxoSmithKline
“We welcome today’s announcement of a review to explore the economic issues surrounding antimicrobial resistance..."
1 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for a fixed dose combination of the inhaled corticosteroid, fluticasone furoate and the long-acting beta2 agonist, vilanterol...
30 June 2014 | By GlaxoSmithKline
GSK and Save the Children announced the launch of their second annual $1 million Healthcare Innovation Award at the Partnership for Maternal, Newborn and Child Health meeting in South Africa...
26 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™)...
16 June 2014 | By GlaxoSmithKline
New data from secondary analyses of four randomised phase III studies being presented at the 74th Scientific Sessions of the American Diabetes Association...
11 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse™ Ellipta®...
6 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a pivotal phase III study, LATITUDE-TIMI 60, to evaluate the effects of losmapimod in patients presenting with acute coronary syndrome...
3 June 2014 | By kdc communication
GlaxoSmithKline’s quest for improved anti-malarial treatments has been revolutionized by the speed and reliability of the HP D300 Digital Dispenser...
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
23 May 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare for umeclidinium...
21 May 2014 | By GlaxoSmithKline
GSK announced that it will freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance support...
20 May 2014 | By GlaxoSmithKline
GlaxoSmithKline plc presented data at the American Thoracic Society (ATS) from a late-stage clinical study...
29 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for Incruse® (umeclidinium)...
28 April 2014 | By GlaxoSmithKline
GlaxoSmithKline and Medicines for Malaria Venture announced the start of a phase III global programme to evaluate the efficacy and safety of tafenoquine...
